Related Experiment Video
Updated: Aug 19, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Immunomodulatory changes in patients with colorectal cancer
J Ordemann1, C A Jacobi, C Braumann
1Department of General, Visceral, Vascular, Thoracic Surgery, Charité, Medical School, Medical Faculty, Humboldt University, Berlin, Germany.
Background And Aims:
Solid tumors are frequently accompanied by a depressed cellular and humoral immunity. This study analyzed changes these factors in colorectal cancer patients.
Patients And Methods:
We compared cellular (leukocytes, lymphocytes, HLA-DR expression on monocytes) and humoral immune parameters (interleukin-6, interleukin-10, tumor necrosis factor alpha) in 40 patients with colorectal cancer and in 18 healthy controls.
Results:
Leukocytes were in the normal range in patients and controls. However, tumor patients showed significant lymphopenia in comparison to controls. HLA-DR antigen expression on CD14+ monocytes was reduced in the cancer patients while IL-6 and IL-10 plasma levels were increased. Patients with UICC stage III had IL-6 and IL-10 concentrations were significantly increased as well.
Conclusions:
These findings suggest that colorectal tumor establishment and progression results in a malfunction of the immune system, and underline the importance of elucidating in detail the mechanisms of immune modulation in cancer patients.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Crohn's Disease

